Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998013 | 0.92 | TRPV3 (0.42) | FFAR4FFAR1KDM4EGAAHDAC1 | |
| SCHEMBL2006662 | 0.91 | PPARA (0.43) | FFAR4KDM4ECNR1PPARAPPARG | |
| SCHEMBL2004288 | 0.91 | MTNR1A (0.40) | KDM4EGAAHDAC1CNR1PPARA | |
| SCHEMBL4237361 | 0.85 | TRPV1 (0.42) | KDM4EHDAC1PPARAPPARGPPARD | |
| SCHEMBL2008027 | 0.84 | PPARA (0.42) | KDM4EPPARAPPARGPPARDDRD4 | |
| SCHEMBL2003376 | 0.83 | DRD4 (0.37) | KDM4EHDAC1HDAC2PPARDDRD4 | |
| SCHEMBL1999972 | 0.82 | PPARA (0.43) | KDM4EPPARAPPARGPPARDDRD4 | |
| SCHEMBL2006018 | 0.81 | PPARD (0.51) | FFAR4FFAR1PPARAABL1PPARD | |
| SCHEMBL2026488 | 0.77 | PPARA (0.35) | KDM4EKMT2APPARAPPARGPPARD | |
| SCHEMBL2004822 | 0.77 | PPARA (0.40) | KDM4EGAACNR1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | KLKB1 3000/4885FFAR4 43/4885FFAR1 47/4885 |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | KLKB1 3000/4885FFAR4 43/4885FFAR1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.